Attention is focusing on whether Onureg will be able to be listed on the insurance benefit list. According to related industries, Onureg of BMS Pharmaceutical Korea is expected to be submitted to the HIRA Cancer Disease Review Committee on the 2nd of next month. Onureg is the only oral maintenance of acute myeloid leukemia. It was approved in Korea in March as a treatment for adult patients with acute myeloid leukemia who achieved CRi or incomplete hematological recovery after induction therapy and were not suitable for hematopoietic stem cell transplantation (HSCT). Acute myeloid leukemia is also fatal among leukemia. Without treatment, 90% of people die within a year. Even if it becomes CR, the risk of recurrence is